Barbara Jagodzinska, Ph.D.

Drug Discovery Laboratory, Department of Neurology, David Geffen School of Medicine at UCLA

Drug Discovery Laboratory
710 Westwood Plaza, Reed Building - Room 3256
Los Angeles, CA 90095-1769
Tel: (310) 206-4708
Fax: (310) 825-6956
Email: bjagodzinska@mednet.ucla.edu

Biography

Dr. Jagodzinska is a medicinal chemist, a member of the Drug Discovery & Translational Laboratory at the Department of Neurology at UCLA with many years of drug discovery experience in the pharmaceutical industry (Elan Pharmaceuticals, Novartis, and Kelsius Inc.). She is a member of the Alzheimer’s Disease Program in the Mary S. Easton Center for Alzheimer's Disease that is under the direction of Professor Dale E. Bredesen, M.D., Visiting Professor of Neurology, Department of Neurology, UCLA. For the last several years, Dr. Jagodzinska consulted the Alzheimer's Drug Development Network (ADDN), a network that was originally co-founded by Drs. John and Bredesen at the Buck Institute for Research on Aging in Novato. At ADDN, she focused on drug discovery with novel targets in neurodegenerative diseases and AD through analog and small molecule optimization for potency and bioavailability. In collaboration with the Dominican University of California, she established a Medicinal Chemistry Laboratory for the preparation and characterization of analogs.

During her tenure at Elan Pharmaceuticals, Dr. Jagodzinska was part of the γ-secretase and BACE inhibitor program teams. Systematically synthesized a family of inhibitors and identified a target-specific nanomolar lead candidates as effective inhibitors of APP processing. She acted as a liaison between Chemistry and Pharmacology during the optimization phase of the AD project during a collaboration between Elan and Pharmacia, later Pfizer.

Dr. Jagodzinska is an author of over 20 publications and issued or pending patents on compounds and analogs for CNS-related targets.

Specialty

Medicinal Chemistry, Drug Discovery, Analoging by searching and pharmacophore building based on SAR, Alzheimer's disease.

Affiliations

Drug Discovery Laboratory (DDL)

Education and Degrees

Ph.D. Natural Product Chemistry, University of Warsaw, Poland

Fellow, Dr. Carl Djerassi Laboratory, Stanford University, USA

Publications

(selected peer-reviewed publications)

Sealy JM, Truong AP, Tso L, Probst GD, Aquino J, Hom RK, Jagodzinska BM, Dressen D, Wone DWG, Brogley L, John V, Tung JS, Pleiss MA, Tucker JA, Konradi AW, Dappen MS, Toth G, Pan H, Ruslim L, Miller J, Bova MP, Sinha S, Quinn KP, Sauer JM. Design and synthesis of cell potent BACE-1 inhibitors: Structure-activity relationship of P1' substituents. Bioorganic & Medicinal Chemistry Letters 2009;19(22):6386-6391. PMID: 19811916

Probst GD, Bowers S, Sealy JM, Stupi B, Dressen D, Jagodzinska BM, Aquino J, Gailunas A, Truong AP, Tso L, Xu YZ, Hom RK, John V, Tung JS, Pleiss MA, Tucker JA, Konradi AW, Sham HL, Jagodzinski J, Toth G, Brecht E, Yao N, Pan H, Lin M, Artis DR, Ruslim L, Bova MP, Sinha S, Yednock TA, Gauby S, Zmolek W, Quinn KP, Sauer JM. Design and synthesis of hydroxyethylamine (HEA) BACE-1 inhibitors: Structure-activity relationship of the aryl region. Bioorganic & Medicinal Chemistry Letters 2010;20(20):6034-6039. PMID: 20822903

Descamps O, Spilman P, Zhang Q, Libeu CP, Poksay K, Gorostiza O, Campagna J, Jagodzinska B, Bredesen DE, John V. AβPP-Selective BACE Inhibitors (ASBI): Novel Class of Therapeutic Agents for Alzheimer's Disease. Journal of Alzheimer's Disease 2013;37(2):343-355. PMID: 23948888; PMCID: PMC3971881

Alam MP, Jagodzinska B, Campagna J, Spilman P, John V. C-O bond formation in a microfluidic reactor: high yield SNAr substitution of heteroaryl chlorides. Tetrahedron Letter 2016;57(19):2059-2062. doi:10.1016/j.tetlet.2016.03.095